Event-Related Potentials in Major Depressive Disorder

Young-Min Park

doi:10.4306/jknpa.2019.58.2.125

Journal List > J Korean Neuropsychiatr Assoc > v.58(2) > 1126752

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park: Event-Related Potentials in Major Depressive Disorder

Special Article

The Clinical Use of Electroencephalography in Psychiatry

Journal of Korean Neuropsychiatric Association 2019; 58(2): 125-129.

Published online: 31 May 2019

DOI: https://doi.org/10.4306/jknpa.2019.58.2.125

Event-Related Potentials in Major Depressive Disorder

Young-Min Park, MD, PhD

Department of Psychiatry, Inje University College of Medicine, Goyang, Korea.

Address for correspondence: Young-Min Park, MD, PhD. Department of Psychiatry, Inje University College of Medicine, 170 Juhwa-ro, Ilsanseo-gu, Goyang 10380, Korea. Tel +82-31-910-7260, Fax +82-31-910-7268, medipark@hanmail.net

Received 27 April 2019 Revised 5 May 2019 Accepted 6 May 2019

Korean Neuropsychiatric Association

Abstract

Many event-related potentials (ERPs) studies have been performed in major depressive disorder. ERPs include P50, N170, loudness dependence of auditory evoked potentials (LDAEP), P300, and mismatch negativity (MMN). These ERPs have good time-resolution as noninvasive methods, so they can be used easily in clinical practice and research. For example, ERPs can be used to differentiate patients from healthy people, as well as for assessing the subtype and severity, investigating the psychopathology, and predicting the treatment response in mental disorders. This review focuses on P50, N170, LDAEP, P300, and MMN in major depressive disorders.

Keywords: P50, N100, N170, P200, P300, Loudness dependence of auditory evoked potentials, Mismatch negativity

Notes

^{Conflicts of Interest} The authors have no financial conflicts of interest.

References

1. Wegrzyn J. P50 sensory gating disorders of auditory evoked potentials (AEP) in persons with schizophrenia. Psychiatr Pol. 2004; 38:833–845.

2. Dissanayake DW, Mason R, Marsden CA. Sensory gating, cannabinoids and schizophrenia. Neuropharmacology. 2013; 67:66–77.

3. Wang Y, Fang YR, Chen XS, Chen J, Wu ZG, Yuan CM, et al. A follow-up study on features of sensory gating P50 in treatment-resistant depression patients. Chin Med J (Engl). 2009; 122:2956–2960.

4. Hutchison AK, Hunter SK, Wagner BD, Calvin EA, Zerbe GO, Ross RG. Diminished infant P50 sensory gating predicts increased 40-month-old attention, anxiety/depression, and externalizing symptoms. J Atten Disord. 2017; 21:209–218.

5. Jensen KS, Oranje B, Wienberg M, Glenthøj BY. The effects of increased serotonergic activity on human sensory gating and its neural generators. Psychopharmacology (Berl). 2008; 196:631–641.

6. Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry. 2005; 162:386–388.

7. Eimer M, Holmes A, McGlone FP. The role of spatial attention in the processing of facial expression: an ERP study of rapid brain responses to six basic emotions. Cogn Affect Behav Neurosci. 2003; 3:97–110.

8. Blau VC, Maurer U, Tottenham N, McCandliss BD. The face-specific N170 component is modulated by emotional facial expression. Behav Brain Funct. 2007; 3:7.

9. Zhang D, He Z, Chen Y, Wei Z. Deficits of unconscious emotional processing in patients with major depression: an ERP study. J Affect Disord. 2016; 199:13–20.

10. McCleery A, Lee J, Joshi A, Wynn JK, Hellemann GS, Green MF. Meta-analysis of face processing event-related potentials in schizophrenia. Biol Psychiatry. 2015; 77:116–126.

11. Chen J, Ma W, Zhang Y, Wu X, Wei D, Liu G, et al. Distinct facial processing related negative cognitive bias in first-episode and recurrent major depression: evidence from the N170 ERP component. PLoS One. 2014; 9:e109176.

12. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993; 33:173–187.

13. Hegerl U, Gallinat J, Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord. 2001; 62:93–100.

14. Linka T, Müller BW, Bender S, Sartory G. The intensity dependence of the auditory evoked N1 component as a predictor of response to citalopram treatment in patients with major depression. Neurosci Lett. 2004; 367:375–378.

15. Linka T, Müller BW, Bender S, Sartory G, Gastpar M. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry. 2005; 38:139–143.

16. Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, et al. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry. 2007; 68:1206–1212.

17. Park YM, Kim DW, Kim S, Im CH, Lee SH. The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder. Psychopharmacology (Berl). 2011; 213:625–632.

18. Lee BH, Park YM, Lee SH, Shim M. Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder. Int J Mol Sci. 2015; 16:6251–6265.

19. Park YM, Lee SH, Kim S, Bae SM. The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34:313–316.

20. Fukuda K. Integrated theory to unify status among schizophrenia and manic depressive illness. Med Hypotheses. 2015; 85:506–511.

21. Liu B, Liu J, Wang M, Zhang Y, Li L. From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Front Cell Neurosci. 2017; 11:305.

22. Park YM, Jung E, Kim HS, Hahn SW, Lee SH. Differences in central serotoninergic transmission among patients with recent onset, subchronic, and chronic schizophrenia as assessed by the loudness dependence of auditory evoked potentials. Schizophr Res. 2015; 168:180–184.

23. Fitzgerald PB, Mellow TB, Hoy KE, Segrave R, Cooper NR, Upton DJ, et al. A study of intensity dependence of the auditory evoked potential (IDAEP) in medicated melancholic and non-melancholic depression. J Affect Disord. 2009; 117:212–216.

24. Lee SH, Park YC, Yoon S, Kim JI, Hahn SW. Clinical implications of loudness dependence of auditory evoked potentials in patients with atypical depression. Prog Neuropsychopharmacol Biol Psychiatry. 2014; 54:7–12.

25. Park YM, Lee SH. Can the loudness dependence of auditory evoked potentials and suicidality be used to differentiate between depressive patients with and without bipolarity. Psychiatry Investig. 2013; 10:143–147.

26. Juckel G, Hegerl U. Evoked potentials, serotonin, and suicidality. Pharmacopsychiatry. 1994; 27:Suppl 1. 27–29.

27. Kim DH, Park YM. The association between suicidality and serotonergic dysfunction in depressed patients. J Affect Disord. 2013; 148:72–76.

28. Chen TJ, Yu YW, Chen MC, Wang SY, Tsai SJ, Lee TW. Serotonin dysfunction and suicide attempts in major depressives: an auditory event-related potential study. Neuropsychobiology. 2005; 52:28–36.

29. Graßnickel V, Illes F, Juckel G, Uhl I. Loudness dependence of auditory evoked potentials (LDAEP) in clinical monitoring of suicidal patients with major depression in comparison with non-suicidal depressed patients and healthy volunteers: a follow-up-study. J Affect Disord. 2015; 184:299–304.

30. Park YM. Relationship between serotonergic dysfunction based on loudness dependence of auditory-evoked potentials and suicide in patients with major depressive disorder. Psychiatry Investig. 2015; 12:421–424.

31. Jaworska N, De Somma E, Blondeau C, Tessier P, Norris S, Fusee W, et al. Auditory P3 in antidepressant pharmacotherapy treatment responders, non-responders and controls. Eur Neuropsychopharmacol. 2013; 23:1561–1569.

32. Olbrich S, Arns M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int Rev Psychiatry. 2013; 25:604–618.

33. Işntaş M, Ak M, Erdem M, Oz O, Ozgen F. Event-related potentials in major depressive disorder: the relationship between P300 and treatment response. Turk Psikiyatri Derg. 2012; 23:33–39.

34. Bruder GE, Kayser J, Tenke CE, Leite P, Schneier FR, Stewart JW, et al. Cognitive ERPs in depressive and anxiety disorders during tonal and phonetic oddball tasks. Clin Electroencephalogr. 2002; 33:119–124.

35. Vandoolaeghe E, Van Hunsel F, Nuyten D, Maes M. Auditory event related potentials in major depression: prolonged P300 latency and increased P200 amplitude. J Affect Disord. 1998; 48:105–113.

36. Kalayam B, Alexopoulos GS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry. 1999; 56:713–718.

37. Kenemans JL, Kähkönen S. How human electrophysiology informs psychopharmacology: from bottom-up driven processing to topdown control. Neuropsychopharmacology. 2011; 36:26–51.

38. Chen J, Zhang Y, Wei D, Wu X, Fu Q, Xu F, et al. Neurophysiological handover from MMN to P3a in first-episode and recurrent major depression. J Affect Disord. 2015; 174:173–179.

39. Qiao Z, Yu Y, Wang L, Yang X, Qiu X, Zhang C, et al. Impaired preattentive change detection in major depressive disorder patients revealed by auditory mismatch negativity. Psychiatry Res. 2013; 211:78–84.

TOOLS

Similar articles